MCID: ALK016
MIFTS: 49

Alk-Negative Anaplastic Large Cell Lymphoma

Categories: Blood diseases, Cancer diseases, Immune diseases, Rare diseases

Aliases & Classifications for Alk-Negative Anaplastic Large Cell Lymphoma

MalaCards integrated aliases for Alk-Negative Anaplastic Large Cell Lymphoma:

Name: Alk-Negative Anaplastic Large Cell Lymphoma 59
Anaplastic Large Cell Lymphoma, Alk Negative 73
Anaplastic Large Cell Lymphoma, Alk-Positive 73
Alk- Anaplastic Large Cell Lymphoma 59
Alk- Alcl 59

Characteristics:

Orphanet epidemiological data:

59
alk-negative anaplastic large cell lymphoma
Inheritance: Not applicable; Age of onset: Adult;

Classifications:



External Ids:

Orphanet 59 ORPHA300903
UMLS via Orphanet 74 C1332078
ICD10 via Orphanet 34 C84.7
ICD10 33 C84.7

Summaries for Alk-Negative Anaplastic Large Cell Lymphoma

MalaCards based summary : Alk-Negative Anaplastic Large Cell Lymphoma, also known as anaplastic large cell lymphoma, alk negative, is related to alk-positive anaplastic large cell lymphoma and lymphoma. An important gene associated with Alk-Negative Anaplastic Large Cell Lymphoma is ALK (ALK Receptor Tyrosine Kinase), and among its related pathways/superpathways are ERK Signaling and PEDF Induced Signaling. The drugs Cyclophosphamide and Gemcitabine have been mentioned in the context of this disorder. Affiliated tissues include t cells, bone and breast, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and Synthetic lethal with MLN4924 (a NAE inhibitor)

Related Diseases for Alk-Negative Anaplastic Large Cell Lymphoma

Diseases in the Alk-Positive Anaplastic Large Cell Lymphoma family:

Alk-Negative Anaplastic Large Cell Lymphoma

Diseases related to Alk-Negative Anaplastic Large Cell Lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 53)
# Related Disease Score Top Affiliating Genes
1 alk-positive anaplastic large cell lymphoma 32.7 ALK STAT3
2 lymphoma 31.5 ALK BAX BCL2 MYC
3 peripheral t-cell lymphoma 30.6 ALK CCR4 CXCR3
4 anaplastic large cell lymphoma 11.0
5 myelodysplastic syndrome 10.2
6 sarcoma 10.2
7 capillary leak syndrome 10.2
8 ichthyosis 10.2
9 hypereosinophilic syndrome 10.2
10 ichthyosis, acquired 10.2
11 lymphomatoid papulosis 10.2
12 soft tissue sarcoma 10.2
13 systemic capillary leak syndrome 10.2
14 high grade b-cell lymphoma with myc and/ or bcl2 and/or bcl6 rearrangement 10.2 BCL2 MYC
15 diffuse large b-cell lymphoma of the central nervous system 10.1 BCL2 MYC
16 differentiated thyroid carcinoma 10.1 ALK BCL2 CD274
17 kashin-beck disease 10.1 BAX BCL2
18 chronic venous leg ulcers 10.1 BCL2 MYC
19 lymphoma, hodgkin, classic 10.1
20 asthma 10.1
21 hematopoietic stem cell transplantation 10.1
22 pemphigus foliaceus 10.1
23 lymphocytic leukemia 10.1
24 syphilis 10.1
25 malignant teratoma 10.1 BAX BCL2
26 oral lichen planus 10.1 BAX CXCR3 TP63
27 primary mediastinal large b-cell lymphoma 10.1 BCL2 CD274 MYC
28 suppressor of tumorigenicity 3 10.1 BAX BCL2 MYC
29 myasthenic syndrome, congenital, 14 10.0 CD274 MYC
30 primary central nervous system lymphoma 10.0 BCL2 CD274
31 pleomorphic carcinoma 10.0 ALK CD274
32 hematologic cancer 10.0 ADA ALK BAX MYC
33 respiratory system cancer 9.9 ALK CD274 MYC STAT3
34 focal cortical dysplasia, type ii 9.9 BAX BCL2 BCL2L1
35 apical myocardial infarction 9.9 BCL2L1 STAT3
36 leukocyte disease 9.9 BAX BCL2L1 MYC
37 acute promyelocytic leukemia 9.8 BAX BCL2 MYC STAT3
38 follicular lymphoma 9.8 BCL2 BCL2L1 MYC
39 breast adenocarcinoma 9.8 BAX BCL2L1 MYC
40 mycosis fungoides 9.8 CCR4 CXCR3 DPP4 STAT3
41 b-cell lymphomas 9.7 BAX BCL2 BCL2L1 MYC
42 burkitt lymphoma 9.7 BAX BCL2 BCL2L1 MYC
43 cervical cancer 9.7 BAX BCL2 MYC STAT3 TP63
44 mantle cell lymphoma 9.7 BCL2 BCL2L1 MYC PMAIP1
45 lymphoma, non-hodgkin, familial 9.7 ALK BAX BCL2 BCL2L1 MYC
46 large intestine cancer 9.7 BCL2L1 CD274 MYC STAT3
47 lung cancer susceptibility 3 9.6 ALK BCL2L1 STAT3 TP63
48 squamous cell carcinoma, head and neck 9.6 BCL2L1 MYC STAT3 TP63
49 nasopharyngeal carcinoma 9.6 BCL2 BCL2L1 MYC STAT3
50 myeloma, multiple 9.6 BCL2L1 MYC PMAIP1 STAT3

Graphical network of the top 20 diseases related to Alk-Negative Anaplastic Large Cell Lymphoma:



Diseases related to Alk-Negative Anaplastic Large Cell Lymphoma

Symptoms & Phenotypes for Alk-Negative Anaplastic Large Cell Lymphoma

GenomeRNAi Phenotypes related to Alk-Negative Anaplastic Large Cell Lymphoma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.32 BAX BCL2 BCL2L1 DUSP22
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.32 BAX BCL2 BCL2L1 DUSP22 MYC TP63

MGI Mouse Phenotypes related to Alk-Negative Anaplastic Large Cell Lymphoma:

46 (show all 14)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.2 ADA ALK BAX BCL2 BCL2L1 CD274
2 behavior/neurological MP:0005386 10.19 ADARB1 ALK BAX BCL2 BCL2L1 CD274
3 growth/size/body region MP:0005378 10.19 ADA ADARB1 ALK BAX BCL2 BCL2L1
4 cellular MP:0005384 10.18 ADA BAX BCL2 BCL2L1 CD274 CXCR3
5 endocrine/exocrine gland MP:0005379 10.16 ADA ALK BAX BCL2 BCL2L1 DPP4
6 hematopoietic system MP:0005397 10.13 ADA BAX BCL2 BCL2L1 CCR4 CD274
7 immune system MP:0005387 10.13 ADA BAX BCL2 BCL2L1 CCR4 CD274
8 mortality/aging MP:0010768 10.11 ADA ADARB1 ALK BAX BCL2 BCL2L1
9 integument MP:0010771 9.95 ALK BCL2 BCL2L1 CD274 MYC STAT3
10 muscle MP:0005369 9.87 ADA ADARB1 BAX BCL2 MYC STAT3
11 neoplasm MP:0002006 9.86 ALK BAX BCL2 BCL2L1 CXCR3 MYC
12 renal/urinary system MP:0005367 9.63 ADA BAX BCL2 CXCR3 STAT3 TP63
13 reproductive system MP:0005389 9.56 ADA ALK BAX BCL2 BCL2L1 MYC
14 respiratory system MP:0005388 9.17 ADA ALK BAX CCR4 CXCR3 STAT3

Drugs & Therapeutics for Alk-Negative Anaplastic Large Cell Lymphoma

Drugs for Alk-Negative Anaplastic Large Cell Lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 44)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cyclophosphamide Approved, Investigational Phase 4 6055-19-2, 50-18-0 2907
2
Gemcitabine Approved Phase 4 95058-81-4 60750
3
Vincristine Approved, Investigational Phase 4 57-22-7, 2068-78-2 5978
4
Etoposide Approved Phase 4 33419-42-0 36462
5
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
6
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
7
Cisplatin Approved Phase 4 15663-27-1 2767 441203 84093
8
Ifosfamide Approved Phase 4 3778-73-2 3690
9
Epirubicin Approved Phase 4 56420-45-2 41867
10
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
11
Mechlorethamine Approved, Investigational Phase 4 51-75-2 4033
12
Methotrexate Approved Phase 4 59-05-2, 1959-05-2 126941
13
leucovorin Approved Phase 4 58-05-9 6006 143
14
Doxorubicin Approved, Investigational Phase 4 23214-92-8 31703
15
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
16
Doxil Approved June 1999 Phase 4 31703
17
Pirarubicin Investigational Phase 4 72496-41-4
18
Isophosphamide mustard Phase 4 0
19 Hormone Antagonists Phase 4
20 Anti-Bacterial Agents Phase 4
21 Antineoplastic Agents, Alkylating Phase 4
22 Topoisomerase Inhibitors Phase 4
23 Antibiotics, Antitubercular Phase 4
24 Immunologic Factors Phase 4
25 Antineoplastic Agents, Hormonal Phase 4
26 Antimitotic Agents Phase 4
27 Alkylating Agents Phase 4
28 Hormones Phase 4
29 Anti-Inflammatory Agents Phase 4
30 Antineoplastic Agents, Phytogenic Phase 4
31 Immunosuppressive Agents Phase 4
32 BB 1101 Phase 4
33 Etoposide phosphate Phase 4
34 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4
35 Antirheumatic Agents Phase 4
36 glucocorticoids Phase 4
37 Folic Acid Antagonists Phase 4
38 Dermatologic Agents Phase 4
39 Vitamin B Complex Phase 4
40 Antimetabolites Phase 4
41 Folate Phase 4
42 Antimetabolites, Antineoplastic Phase 4
43 Vitamin B9 Phase 4
44 Nucleic Acid Synthesis Inhibitors Phase 4

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 CEOP/IVE/GDP Compared With CEOP as the First-line Therapy for Newly Diagnosed Adult Patients With PTCL Unknown status NCT02533700 Phase 4 CEOP/IVE/GDP chemotherapy regimen;CEOP chemotherapy regimen for 6 cycles
2 CTOP/ITE/MTX Compared With CHOP as the First-line Therapy for Newly Diagnosed Young Patients With T Cell Lymphoma Active, not recruiting NCT01746992 Phase 4 Cyclophosphamide 750mg/m2;Vincristine 1.4mg/m2;Doxorubicin 50mg/m2;prednisone 60mg/m2;ifosfamide 2000mg/m2;pirarubicin 50mg/m2;pirarubicin 25mg/m2;Etoposide phosphate 100mg/m2;methotrexate 1500mg/m2
3 A Study of BGB-A317 in Patients With Relapsed or Refractory Mature T- and NK- Neoplasms Recruiting NCT03493451 Phase 2 BGB A317

Search NIH Clinical Center for Alk-Negative Anaplastic Large Cell Lymphoma

Genetic Tests for Alk-Negative Anaplastic Large Cell Lymphoma

Anatomical Context for Alk-Negative Anaplastic Large Cell Lymphoma

MalaCards organs/tissues related to Alk-Negative Anaplastic Large Cell Lymphoma:

41
T Cells, Bone, Breast, Bone Marrow, Lung, Thyroid, B Cells

Publications for Alk-Negative Anaplastic Large Cell Lymphoma

Articles related to Alk-Negative Anaplastic Large Cell Lymphoma:

(show top 50) (show all 55)
# Title Authors Year
1
The Long Non-Coding RNA MIR503HG Enhances Proliferation of Human ALK-Negative Anaplastic Large-Cell Lymphoma. ( 29758012 )
2018
2
Targetable fusions of the FRK tyrosine kinase in ALK-negative anaplastic large cell lymphoma. ( 29026208 )
2018
3
FOXP3-positive T-cell lymphomas in non-HTLV1 carriers include ALK-negative anaplastic large cell lymphoma: expanding the Spectrum of T-cell lymphomas with regulatory phenotype. ( 29898383 )
2018
4
Prognostic factors of ALK-negative anaplastic large-cell lymphoma: a single-institution experience. ( 29359238 )
2018
5
Acquired ichthyosis as a paraneoplastic feature of ALK-negative anaplastic large cell lymphoma. ( 30407628 )
2018
6
ALK-Negative Anaplastic Large Cell Lymphoma Presenting as an Extranodal Soft-Tissue Mass With an Unusual Alveolar Growth Pattern: A Diagnostic Challenge. ( 28381153 )
2017
7
DUSP22 and TP63 rearrangements predict outcome of ALK-negative anaplastic large cell lymphoma: a Danish cohort study. ( 28522440 )
2017
8
PD-L1 is commonly expressed and transcriptionally regulated by STAT3 and MYC in ALK-negative anaplastic large-cell lymphoma. ( 28344319 )
2017
9
Indolent ALK-Negative Anaplastic Large Cell Lymphoma, DUSP22 Rearranged, with an Unusual Immunophenotype in an HIV Patient. ( 28042680 )
2017
10
Secondary CNS involvement of ALK-negative anaplastic large cell lymphoma. ( 28370436 )
2017
11
ALK-negative anaplastic large cell lymphoma with urinary bladder involvement diagnosed in urine cytology: A case report and literature review. ( 28139895 )
2017
12
The masquerading presentation of a systemic anaplastic large cell lymphoma, ALK positive: a case report and review of the literature. ( 28441913 )
2017
13
Complete response in a critically ill patient with ALK-negative anaplastic large cell lymphoma treated with single agent brentuximab-vedotin. ( 26809026 )
2016
14
Clinical and prognostic differences between ALK-negative anaplastic large cell lymphoma and peripheral T cell lymphoma, not otherwise specified: a single institution experience. ( 27209536 )
2016
15
ALK-negative anaplastic large cell lymphoma with CNS involvement needs more than just brentuximab vedotin. ( 27460479 )
2016
16
ALK-negative anaplastic large cell lymphoma with loss of CD30 expression during treatment with brentuximab vedotin. ( 27263791 )
2016
17
Primary rare anaplastic large cell lymphoma, ALK positive in small intestine: case report and review of the literature. ( 27612448 )
2016
18
ALK-negative anaplastic large-cell lymphoma. ( 26769771 )
2016
19
ALK-negative anaplastic large cell lymphoma is sensitive to bortezomib through Noxa upregulation and release of Bax from Bcl-2. ( 25975837 )
2015
20
Primary pancreatic ALK negative anaplastic large cell lymphoma. ( 25474521 )
2015
21
A case of ALK negative anaplastic large cell lymphoma with leukaemic manifestation, transformed from CD4 positive T-cell large granular lymphocytic leukaemia. ( 25474523 )
2015
22
Progress in the identification of subgroups in ALK-negative anaplastic large-cell lymphoma. ( 26223379 )
2015
23
Axillary Lymphadenopathy: An Outstanding Presentation for Breast Implant-Associated ALK-Negative Anaplastic Large Cell Lymphoma. ( 25829459 )
2015
24
PAX5-expressing ALK-negative anaplastic large cell lymphoma with extensive extranodal and nodal involvement. ( 26187868 )
2015
25
Flow cytometry of ALK-negative anaplastic large cell lymphoma of breast implant-associated effusion and capsular tissue. ( 24976005 )
2014
26
ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes. ( 24894770 )
2014
27
Flow cytometry of ALK-negative anaplastic large cell lymphoma of breast implant-associated effusion and capsular tissue. ( 25044944 )
2014
28
Breast implant-associated ALK-negative anaplastic large cell lymphoma: a case report and discussion of possible pathogenesis. ( 23923082 )
2013
29
Intravascular ALK-negative anaplastic large cell lymphoma with localized cutaneous involvement and an indolent clinical course: toward recognition of a distinct clinicopathologic entity. ( 23480896 )
2013
30
Composite ALK-negative anaplastic large cell lymphoma and small lymphocytic lymphoma involving the right inguinal lymph node. ( 24169448 )
2013
31
Refractory Case of ALK-Negative Anaplastic Large-Cell Lymphoma with PAX-5 Expression and T-Cell Receptor-I^ Gene Rearrangement. ( 24369229 )
2013
32
ALK-negative anaplastic large cell lymphoma primarily involving the bronchus: a case report and literature review. ( 24427373 )
2013
33
Lymphohistiocytic and small cell pattern of anaplastic large cell lymphoma, ALK positive, arising in an 86-year-old woman. ( 23692425 )
2013
34
Two cases of CD30+, anaplastic lymphoma kinase (ALK)-negative anaplastic large cell lymphoma with oral manifestations. ( 22940020 )
2013
35
Systemic Capillary Leak Syndrome as an Initial Presentation of ALK-Negative Anaplastic Large Cell Lymphoma. ( 22953081 )
2012
36
Identification of a 3-gene model as a powerful diagnostic tool for the recognition of ALK-negative anaplastic large-cell lymphoma. ( 22740451 )
2012
37
High-risk ALK negative anaplastic large-cell lymphoma presenting with hypereosinophilic syndrome in a 2.5-year-old child. ( 23013405 )
2012
38
Anaplastic large cell lymphoma, ALK-positive. ( 22440390 )
2012
39
Leukemic presentation of ALK-negative anaplastic large cell lymphoma in a patient with myelodysplastic syndrome. ( 22246491 )
2012
40
Pathobiology of ALK-negative anaplastic large cell lymphoma. ( 22053281 )
2011
41
ALK-negative anaplastic large cell lymphoma mimicking a soft tissue sarcoma. ( 22090705 )
2011
42
Rapid fatal pulmonary complications in a Chinese patient after bortezomib treatment for ALK-negative anaplastic large-cell lymphoma. ( 20371451 )
2010
43
Linkage of expression of chemokine receptors (CXCR3 and CCR4) and cytotoxic molecules in peripheral T cell lymphoma, not otherwise specified and ALK-negative anaplastic large cell lymphoma. ( 20217288 )
2010
44
Secondary ALK negative anaplastic large cell lymphoma in a patient with lymphomatoid papulosis of 40 years duration. ( 20644462 )
2010
45
ALK-negative anaplastic large cell lymphoma with extensive peripheral blood and bone marrow involvements manifested as "leukemic phase". ( 19695703 )
2010
46
ALK-negative anaplastic large cell lymphoma in leukemic phase with near-pentaploidy. ( 20846102 )
2010
47
A case of anaplastic large cell lymphoma, ALK positive, primary presented in the skin and relapsed with systemic involvement and leukocytosis after years of follow-up period. ( 20976631 )
2010
48
Cutaneous presentation on the eyelid of primary, systemic, CD30+, anaplastic lymphoma kinase (ALK)-negative, anaplastic large-cell lymphoma (ALCL). ( 16796648 )
2006
49
CD26, together with cell surface adenosine deaminase, is selectively expressed on ALK-positive, but not on ALK-negative, anaplastic large cell lymphoma and Hodgkin's lymphoma. ( 17071493 )
2006
50
Primary pancreatic anaplastic large cell lymphoma, ALK negative: a case report. ( 16273656 )
2005

Variations for Alk-Negative Anaplastic Large Cell Lymphoma

Expression for Alk-Negative Anaplastic Large Cell Lymphoma

Search GEO for disease gene expression data for Alk-Negative Anaplastic Large Cell Lymphoma.

Pathways for Alk-Negative Anaplastic Large Cell Lymphoma

Pathways related to Alk-Negative Anaplastic Large Cell Lymphoma according to GeneCards Suite gene sharing:

(show top 50) (show all 57)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.81 ALK BAX BCL2 BCL2L1 CCR4 CXCR3
2
Show member pathways
13.64 ALK BAX BCL2 BCL2L1 CCR4 CXCR3
3
Show member pathways
13 BAX BCL2 BCL2L1 CCR4 MYC STAT3
4
Show member pathways
12.78 BAX BCL2 BCL2L1 MYC PMAIP1 STAT3
5
Show member pathways
12.74 ALK BAX BCL2 BCL2L1 STAT3
6
Show member pathways
12.7 BAX BCL2 BCL2L1 MYC PMAIP1 TP63
7
Show member pathways
12.65 BAX BCL2 BCL2L1 PMAIP1 STAT3
8
Show member pathways
12.55 BCL2 BCL2L1 MYC STAT3
9
Show member pathways
12.54 BAX BCL2 BCL2L1 MYC STAT3
10
Show member pathways
12.53 BAX BCL2 BCL2L1 STAT3
11 12.52 ALK BAX BCL2 BCL2L1 MYC PMAIP1
12 12.48 BCL2 MYC STAT3 TP63
13
Show member pathways
12.4 BAX BCL2 BCL2L1 MYC STAT3
14
Show member pathways
12.36 BCL2 BCL2L1 MYC STAT3
15
Show member pathways
12.36 BAX BCL2L1 MYC STAT3
16 12.27 BAX BCL2 MYC STAT3
17 12.27 BAX CCR4 PMAIP1 STAT3
18
Show member pathways
12.24 BAX BCL2 BCL2L1 MYC PMAIP1
19
Show member pathways
12.17 BAX BCL2 BCL2L1 MYC
20 12.15 BAX BCL2L1 MYC STAT3
21 12.11 BAX BCL2 BCL2L1 MYC
22
Show member pathways
12.03 BAX BCL2 MYC STAT3
23 12.03 BAX BCL2 BCL2L1 MYC PMAIP1
24
Show member pathways
12.02 BCL2 MYC STAT3
25 12.02 MYC STAT3 TP63
26 12.02 BAX BCL2 PMAIP1 TP63
27
Show member pathways
11.94 BAX BCL2 BCL2L1
28 11.94 BAX BCL2 MYC PMAIP1
29 11.93 BCL2 BCL2L1 MYC STAT3
30
Show member pathways
11.91 BAX PMAIP1 TP63
31 11.87 BAX BCL2 STAT3
32
Show member pathways
11.81 BCL2L1 MYC STAT3
33
Show member pathways
11.8 BCL2 BCL2L1 MYC STAT3
34 11.77 BAX MYC PMAIP1
35 11.76 BAX BCL2 BCL2L1 MYC
36 11.75 ADA BCL2 MYC
37
Show member pathways
11.68 BAX BCL2 BCL2L1 PMAIP1
38
Show member pathways
11.67 BCL2 BCL2L1 MYC
39
Show member pathways
11.65 BAX BCL2 BCL2L1 PMAIP1 TP63
40 11.6 BAX BCL2 BCL2L1 PMAIP1
41 11.53 BCL2L1 MYC STAT3
42 11.53 BAX BCL2 BCL2L1
43
Show member pathways
11.48 BCL2L1 MYC STAT3
44 11.47 BAX BCL2 MYC
45 11.44 BAX BCL2 MYC
46 11.36 BAX BCL2L1 PMAIP1
47 11.33 BCL2L1 MYC STAT3
48 11.27 BAX BCL2 BCL2L1
49
Show member pathways
11.27 BCL2 BCL2L1 MYC STAT3
50
Show member pathways
11.26 BAX BCL2 BCL2L1 PMAIP1

GO Terms for Alk-Negative Anaplastic Large Cell Lymphoma

Cellular components related to Alk-Negative Anaplastic Large Cell Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 external side of plasma membrane GO:0009897 9.56 ADA CCR4 CD274 CXCR3
2 pore complex GO:0046930 9.16 BAX BCL2
3 Bcl-2 family protein complex GO:0097136 8.96 BAX BCL2L1
4 mitochondrial outer membrane GO:0005741 8.92 BAX BCL2 BCL2L1 PMAIP1

Biological processes related to Alk-Negative Anaplastic Large Cell Lymphoma according to GeneCards Suite gene sharing:

(show all 42)
# Name GO ID Score Top Affiliating Genes
1 response to drug GO:0042493 9.95 ADA BCL2 MYC STAT3
2 cytokine-mediated signaling pathway GO:0019221 9.94 BCL2 BCL2L1 MYC STAT3
3 regulation of cell cycle GO:0051726 9.89 ADARB1 BAX BCL2 STAT3
4 negative regulation of neuron apoptotic process GO:0043524 9.86 BAX BCL2 BCL2L1
5 negative regulation of cell migration GO:0030336 9.85 ADARB1 BCL2 DUSP22
6 regulation of apoptotic process GO:0042981 9.85 ALK BAX BCL2 BCL2L1 PMAIP1 TP63
7 cellular response to hypoxia GO:0071456 9.84 BCL2 MYC PMAIP1
8 male gonad development GO:0008584 9.83 BAX BCL2 BCL2L1
9 intrinsic apoptotic signaling pathway in response to DNA damage GO:0008630 9.77 BAX BCL2 BCL2L1
10 response to radiation GO:0009314 9.75 BCL2 BCL2L1 CCR4
11 extrinsic apoptotic signaling pathway in absence of ligand GO:0097192 9.74 BAX BCL2 BCL2L1
12 response to cytokine GO:0034097 9.73 BCL2 BCL2L1 CD274 STAT3
13 response to gamma radiation GO:0010332 9.72 BAX BCL2 MYC
14 regulation of mitochondrial membrane potential GO:0051881 9.71 BAX BCL2 BCL2L1
15 ovarian follicle development GO:0001541 9.71 BAX BCL2 BCL2L1 MYC
16 negative regulation of intrinsic apoptotic signaling pathway GO:2001243 9.69 BCL2 BCL2L1
17 B cell homeostasis GO:0001782 9.68 BAX BCL2
18 homeostasis of number of cells GO:0048872 9.68 BAX CCR4
19 mitochondrion morphogenesis GO:0070584 9.68 BAX BCL2L1
20 positive regulation of smooth muscle cell migration GO:0014911 9.67 BCL2 MYC
21 positive regulation of protein insertion into mitochondrial membrane involved in apoptotic signaling pathway GO:1900740 9.67 BCL2 PMAIP1 TP63
22 positive regulation of protein oligomerization GO:0032461 9.66 BAX PMAIP1
23 endoplasmic reticulum calcium ion homeostasis GO:0032469 9.66 BAX BCL2
24 hypothalamus development GO:0021854 9.65 BAX MYC
25 apoptotic mitochondrial changes GO:0008637 9.65 BAX BCL2 BCL2L1
26 regulation of cysteine-type endopeptidase activity involved in apoptotic process GO:0043281 9.64 BAX TP63
27 positive regulation of ATP biosynthetic process GO:2001171 9.63 MYC STAT3
28 regulation of protein heterodimerization activity GO:0043497 9.63 BAX BCL2
29 protein insertion into mitochondrial membrane involved in apoptotic signaling pathway GO:0001844 9.62 BAX PMAIP1
30 neuron apoptotic process GO:0051402 9.62 BAX BCL2 BCL2L1 TP63
31 regulation of protein homodimerization activity GO:0043496 9.61 BAX BCL2
32 leukocyte homeostasis GO:0001776 9.61 BAX BCL2
33 regulation of cell-cell adhesion mediated by integrin GO:0033632 9.58 ADA DPP4
34 positive regulation of intrinsic apoptotic signaling pathway GO:2001244 9.56 BAX BCL2 BCL2L1 PMAIP1
35 positive regulation of developmental pigmentation GO:0048087 9.52 BAX BCL2
36 regulation of nitrogen utilization GO:0006808 9.51 BAX BCL2
37 release of cytochrome c from mitochondria GO:0001836 9.46 BAX BCL2 BCL2L1 PMAIP1
38 regulation of mitochondrial membrane permeability GO:0046902 9.26 BCL2 BCL2L1 PMAIP1 STAT3
39 cell proliferation GO:0008283 9.23 ALK BAX BCL2 BCL2L1 DUSP22 MYC
40 negative regulation of apoptotic process GO:0043066 10.03 ADA ALK BCL2 BCL2L1 MYC STAT3
41 positive regulation of cell proliferation GO:0008284 10.02 BCL2 BCL2L1 DPP4 MYC STAT3
42 apoptotic process GO:0006915 10 BAX BCL2 BCL2L1 CXCR3 DUSP22 PMAIP1

Molecular functions related to Alk-Negative Anaplastic Large Cell Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.5 ALK BAX BCL2 BCL2L1 DPP4 STAT3
2 C-C chemokine binding GO:0019957 9.37 CCR4 CXCR3
3 C-C chemokine receptor activity GO:0016493 9.32 CCR4 CXCR3
4 chemokine receptor activity GO:0004950 9.26 CCR4 CXCR3
5 adenosine deaminase activity GO:0004000 9.16 ADA ADARB1
6 BH3 domain binding GO:0051434 8.8 BAX BCL2 BCL2L1

Sources for Alk-Negative Anaplastic Large Cell Lymphoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....